A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.

This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.

Start Date16 May 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06448364 / TerminatedPhase 1

FIRST-IN-HUMAN (FIH), OPEN-LABEL, PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY, TOLERABILITY, PK, PD, AND PRELIMINARY CLINICAL ACTIVITY OF PF-07329640 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS.

The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose.
This study is seeking participants who have solid tumors that:
* have advanced (cancer that doesn't disappear or stay away with treatment) or
* has spread to other parts of the body (metastatic).
This includes (but limited to) the following cancer types:
* Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body.
* Colorectal Cancer (CRC): This is a disease where cells in the colon or rectum grow out of control.
* Urothelial Cancer (UC): This is a cancer that starts in the urinary systems.
* Melanoma: Skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control.
All participants in this study will receive the study medication (PF-07329640) as an IV infusion (given directly into a vein) at the study clinic every week for repeating 28-day cycles.
Depending on which part of the study participants are enrolled in they will receive the study medication (PF-07329640 alone or in combination with other anti-cancer medications (bevacizumab or sasanlimab). Bevacizumab is given in the clinic as IV infusion every two weeks and sasanlimab is given as a shot under the skin every 4 weeks.
Participants can continue to take the study medication (PF-07329640) and bevacizumab until their cancer is no longer responding. Participants who are taking sasanlimab may receive it for up to 2 years.
The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective.
Participants will be involved in this study for up to 4 years. During this time, they will have a study visit every week. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.

Start Date09 May 2024

Sponsor / Collaborator

Pfizer Inc.

NCT04822818 / CompletedPhase 3IIT

TRIAL EVALUATING EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19, NESTED IN THE CORIMUNO-19 COHORT

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the most frequent complications of the COVID-19 pandemic. In these conditions, hypoxemia may result from : i) a pulmonary vascular dilatation resulting from an impaired hypoxic pulmonary vasoconstriction and leading to ventilation-perfusion mismatching within the lungs and ii) thrombosis-mediated perfusion defects. Pulmonary vascular dilation might be due to a relative failure of the physiological acute hypoxic pulmonary vasoconstriction, in the context of an over-activation of a regional vasodilatation cascade, as part of a dysfunctional inflammatory process. Perfusion abnormalities associated with pulmonary vascular dilation are suggestive of intrapulmonary shunting toward areas where gas exchange is impaired, ultimately leading to a worsening ventilation-perfusion mismatch, a regional hypoxia and a profound hypoxemia.
Increased plasma levels of VEGF have been reported in moderate to severe COVID-19 pneumonia, highlighting the role of VEGF in the pathophysiology of the disease. A better prognosis has been reported in critically ill patients with lower levels of growth factors, HGF and VEGF-A at the time of ICU admission. Recent data of the study NCT 04275414 by Pang J et al have suggested that patients receiving a single-dose of bevacizumab have improved their oxygen support status in 92% of cases during a 28-day follow-up period, as compared with 62% of cases in an external cohort receiving standard care.
Correcting endothelial permeability and vasodilatation with VEGF-targeted therapy could allow repair damaged vascular endothelium, have an indirect anti-inflammatory effect (limiting alveolar exudation of circulating inflammatory and procoagulant mediators) and improve oxygenation and therefore reduce the proportion of patients with severe forms requiring ICU referral and finally patient death. This clinical trial will therefore focus on the specific efficacy of bevacizumab in COVID-19 patients with severe hypoxemia.

Start Date17 Apr 2021

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

100 Clinical Results associated with Bevacizumab-BVZR

100 Translational Medicine associated with Bevacizumab-BVZR

100 Patents (Medical) associated with Bevacizumab-BVZR

120

Literatures (Medical) associated with Bevacizumab-BVZR

01 Nov 2024·European Journal of Pharmaceutics and Biopharmaceutics

In silico evaluation of corneal patch eluting anti-VEGF agents concept

Article

Author: Heljak, Marcin K. ; Kijeńska-Gawrońska, Ewa ; Gunduz, Oguzhan ; Ilhan, Elif ; Heljak, Marcin K ; Swieszkowski, Wojciech ; Cesur, Sumeyye

This study introduces a novel approach utilizing a temporary drug-eluting hydrogel corneal patch to prevent neovascularization, alongside a numerical predictive tool for assessing the release and transport kinetics of bevacizumab (BVZ) after the keratoplasty. A key focus was investigating the impact of tear film clearance on the release kinetics and drug transport from the designed corneal patch. The proposed tear drug clearance model incorporates the physiological mechanism of lacrimal flow (tear turnover), distinguishing itself from previous models. Validation against experimental data confirms the model's robustness, despite limitations such as a 2D axisymmetrical framework and omission of blink frequency and saccadic eye movements potential effects. Analysis highlights the significant influence of lacrimal flow on ocular drug transport, with the corneal patch extending BVZ residence time compared to topical administration. This research sets the stage for exploring multi-layer drug-eluting corneal patches as a promising therapeutic strategy in ocular health.

08 Aug 2024·Future Oncology

A descriptive analysis of real-world oncology biosimilar use in Japan

Article

Author: Rahshenas, Makan ; Masurkar, Nihar ; Nowacki, Grégoire ; Shelbaya, Ahmed ; Ono, Chiho ; Tajima, Kentaro ; Roth, Joshua A ; Dorman, Stephanie

Aim: To describe patient and treatment characteristics associated with bevacizumab BS-Pfizer, rituximab BS-Pfizer and trastuzumab BS-Pfizer and their reference products in Japan.Methods: This retrospective observational study used an administrative claims database to identify patients with ≥1 biosimilar or reference product prescription from 2019 to 2022 for approved indications. Descriptive statistics were calculated.Results: Overall, 14-39% of biosimilar-prescribed patients initiated therapy with reference products. Biosimilar utilization significantly increased from 2019 to 2022. The most-commonly prescribed concomitant class of therapy with biosimilars was antineoplastic therapy.Conclusion: Reference products were most frequently prescribed among the Japanese cohorts, but substantial and increasing proportions received biosimilars over time. Future studies should extend our initial insights to assess biosimilar clinical outcomes in Japanese settings.

01 Aug 2024·Value in Health

Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data

Article

Author: Lu, Brandon ; Chan, Kelvin K W ; Mercer, Rebecca E ; Nguyen, Lena ; Muñoz, Caroline ; Beca, Jaclyn M ; Adamic, Andrea ; Dvorani, Erind

OBJECTIVESMVASI (Amgen) and Zirabev (Pfizer) are 2 of the earliest bevacizumab biosimilars approved for the first-line treatment of metastatic colorectal cancer (mCRC). We aimed to confirm and quantify the real-world cost savings and cost-effectiveness of MVASI and Zirabev relative to originator bevacizumab for patients with mCRC.METHODSWe conducted a population-based, retrospective cohort study in Ontario, Canada, where originator and biosimilar bevacizumab are universally publicly funded. All mCRC patients who received originator bevacizumab between January 2008 and August 2019 or biosimilar bevacizumab between August 2019 and March 2021 were propensity score matched (1:4) to adjust for baseline differences. Total 1-year patient-level costs (CAD) and effects (life years [LY] and quality-adjusted LYs) were calculated from the public health payer's perspective. Primary outcomes included incremental net monetary benefit and incremental net health benefit (INHB). Sensitivity analyses included a subgroup analysis by biosimilar type (MVASI/Zirabev) and a 2-year analysis.RESULTSThe matched cohort included 747 biosimilar cases and 2945 comparators. Bevacizumab biosimilars were associated with an incremental cost of -$6379 (95%CI: -9417, -3537) (ie, cost saving) and incremental effect of 0.0 (95% CI: -0.02, 0.02) LY and -0.01 (95% CI: -0.03, 0) quality-adjusted LYs gained. Incremental net monetary benefit and INHB estimates were $6331 (95% CI: 6245, 6417) and 0.127 LY (95% CI: 0.125, 0.128), respectively, at a willingness-to-pay threshold of $50 000/life year gained, with all estimates indicating the cost-effectiveness of biosimilar bevacizumab. Cost-effectiveness remained consistent across biosimilar brand subgroups and 2-year sensitivity analyses.CONCLUSIONBevacizumab biosimilars demonstrated real-world cost savings while providing similar survival benefit as originator bevacizumab, confirming the initial expectations of their implementation and supporting health system sustainability.

News (Medical) associated with Bevacizumab-BVZR

07 Mar 2024

·www.prnewswire.com

United States Biosimilar industry Outlook to 2028, Featuring Pfizer, Amgen, Biogen, Viatris and Coherus Biosciences

DUBLIN, March 7, 2024 /PRNewswire/ -- The "US Biosimilar industry outlook to 2028" report has been added to ResearchAndMarkets.com's offering. The US Biosimilar Industry is anticipated to grow at a CAGR of ~40% in the next five years owing to the cost-effective nature of Biosimilar drugs, rising geriatric population, increasing cases of chronic diseases and growing strategic partnerships. The US Biosimilar market is significantly growing due to various reasons such as rising geriatric population, cost effective nature of Biosimilar drugs, increasing cases of chronic diseases and growing strategic partnerships. Biosimilar drugs also tend to be cost effective. The geriatric population in the US has been constantly rising. The ageing population went from ~25,000 per 100,000 people in 1980s to ~54,000 per 100,000 people in 2020s. Most of the aged people cannot afford original drugs and thus, rising geriatric population raises the demand for Biosimilar drugs. Moreover, the cases of chronic diseases also have been rising in the US over the years. In 2020, there were at least 155 million people living with a chronic disease in the US. Such high number of chronic illness cases also raise the demand for the development of cost-effective medicines in the form of Biosimilar drugs. Key trends by Market Segment: By Drug class: In 2022, Monoclonal Antibodies continued to dominate the US Biosimilar Market. These antibodies can be best described as proteins developed in laboratories that are known to act like actual antibodies present in our blood. The reason behind their dominance is that they have been very successful when it comes to treating life threatening diseases such as cancers. Moreover, a treatment involving these antibodies happens to be more precise than any other treatment. Furthermore, these antibodies are known for activating the immune responses for fighting a particular disease. Due to their success rates and ability to stimulate immune responses, they have gained quite a popularity in the US Biosimilar market. By Application: In 2022, Oncology segment dominated the US Biosimilar market. The cancer cases have been rapidly rising in the United States over the years. In 2022, the United State witnessed almost 2 million cancer cases. The rising cases of cancer also results in the demand for the development of effective and efficient treatment of cancer. Monoclonal Antibodies that are used in Biosimilar drugs also have a 58% success rate in treating cancer. Overall, Biosimilar drugs are widely used in the treatment of various types of cancers such as breast cancer, lung cancer, colorectal cancer, etc. There are many Biosimilar drugs such as Zirabev, Truxima, Ogiviri, Releuko, Fulphila, Retacrit, etc which are used in the effective and efficient treatment of Cancer. By Geography: In 2022, the northern region of US happened to be the dominant segment in the US Biosimilar market. The main reason behind its dominance is the presence of Biosimilar drugs manufacturing companies, presence of many other healthcare companies and top-notch hospitals of the country. This is primarily due to the reason that this region witnesses the major healthcare companies of Biosimilar market in the country such as Amgen, Pfizer, Viartis, Biogen, Coherus Biosciences etc. Overall, there are almost 9000 healthcare companies established in this area. Due to the presence of vast number of companies, this region contributes to the growth of US Biosimilar market greatly. There are also many reputed hospitals located in this area such as Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering Cancer Centre, Dana Farber Cancer Institute, Hospitals of University of Pennsylvania, Northwestern Memorial Hospital, Barns-Jewish Hospital, etc. As more and more people visits these hospitals, the healthcare professionals get to know the requirements and demands of the Biosimilar drugs thereby accelerating the US Biosimilar Market. Future Outlook: The US Biosimilar Market is anticipated to witness a growth at a CAGR of 40% between the time period 2022-2028 owing to the rising cases of chronic diseases, rising geriatric population and increasing cases of cancer along with growing strategic partnerships among pharmaceutical companies. The prevalence of chronic diseases have been constantly rising in the United States. In 2020, there were at least 155 million people living with a chronic disease. This number is futher projected to reach 165 million and 170 million in 2025 and 2030 respectively. With rapidly rising cases, the demand for biosimilar drugs will be rising thereby driving the US Biosimilar market. The rising geriatric population also increases the demand for Biosimilar drugs. In the US, the geriatric population has increased from 25 per 100 people in the 1980s to 54 per 100 people in 2020. This number is further anticipated to reach 72 per 100 people in 2030s. With rising geriatric population, the demand for Biosimilar drugs rises as aged population is less likely to afford generic drugs. The rising cases of cancer also have resulted in an increased demand for Biosimilar drugs. Cancer has been rapidly rising in the US with around 2 million cases in 2020. The number is only projected to further increase. Moreover, most of the Biosimilar drugs are used in oncology so the rising cases only increases the demand for Biosimilar drugs thereby fueling the US Biosimilar market. Key Topics Covered: 1. Executive Summary 2. US Biosimilar Market Overview 2.1 Taxonomy of the Market 2.2 Industry Value Chain 2.3 Ecosystem 2.4 Government Regulations/Initiatives for the Market 2.5 Growth Drivers of the US Biosimilar Market 2.6 Issues and Challenges of the US Biosimilar Market 2.7 Impact of COVID-19 on US Biosimilar Market 2.8 SWOT Analysis 3.US Biosimilar Market Size, 2017 - 2022 4. US Biosimilar Market Segmentation 4.1 By Drug Class, 2017 - 2022 4.2 By Application 2017 - 2022 4.3 By Regional Split (North/East/West/South/Central), 2017 - 2022 5. Competitive Landscape 5.1 Mergers and Acquisitions, Joint Ventures, Collaborations, and Agreements 5.2 Strategies Adopted by Leading Players 5.3 Company Profiles Pfizer Amgen Biogen Viatris Coherus Biosciences 6. US Biosimilar Market, 2022-2028 7. US Biosimilar Market, Market Segmentation 7.1 By Drug class, 2022 - 2028 7.2 By Application, 2022 - 2028 7.3 By Regional Split (North/East/West/South/Central), 2022 - 2028 8. Analyst Recommendations For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Biosimilar

02 Mar 2023

·www.biospace.com

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

DALLAS--(BUSINESS WIRE)-- Lantern Pharma, Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo M.D., M.Sc., MBA, as Vice President of Clinical Development, and several additional team members. The expansion of the clinical development team will continue to advance the Harmonic™ trial, a Phase 2 trial for never smokers with NSCLC, as well as the upcoming first-in-human Phase 1 clinical trials for Lantern’s drug candidates LP-184 and LP-284, which are both anticipated to launch in mid-2023. “We are looking forward to the many contributions that Dr. Ewesuedo and our expanded clinical development team will bring to Lantern and our clinical programs,” said Panna Sharma, Lantern’s President and CEO. “They are joining Lantern at a pivotal period in our company’s growth as we advance our drug candidates into and through clinical trials. I am confident in the decades of proven experience of our new team members and their ability to progress Lantern’s drug candidates to improve the lives of cancer patients,” continued Sharma. Dr. Ewesuedo has over 20 years of experience in preclinical, early, and late phase drug development including roles in clinical development leadership at AstraZeneca, Genzyme/Sanofi, Pfizer, Tesaro/GlaxoSmithKline, and Kymera. His leadership and experience have led to the development of several drugs including the successful filings for Trazimera™ (trastuzumab), Nyvepria™ (pegfilgrastim), and Zirabev™ (bevacizumab), while he was at Pfizer. In addition to his industry experience, he also served as a clinical research faculty member at The Ohio State University from 2000-2005. He holds an M.D. from the University of Ibadan, College of Medicine, Ibadan, Nigeria, a M.Sc. in Pharmacology from Ahmadu Bello University, Zaria, Nigeria, and an MBA from St. Mary’s University, Greehey Business School, San Antonio, TX. Dr. Ewesuedo completed his subspecialties training in Hematology and Pediatric Oncology, and Clinical Pharmacology and Pharmacogenomics, at the University of Chicago. Lantern has also recently appointed Ernest Kitt as Head of Clinical Operations. Mr. Kitt has over 20 years of experience in oncology drug development and clinical operations with proven success in bringing drugs to market. He has held clinical oncology leadership positions at companies including Amgen/Onyx, Aptose, and Biosplice. Other additions to the clinical development team include Annum Zhara as a Senior Clinical Trial Project Manager and Brianna MacCrory as a Clinical Trial Navigator. About Lantern Pharma: Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® AI and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. By targeting drugs to patients whose genomic pro them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. Forward-looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at or on the SEC's website at . Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Phase 1Phase 2Executive Change

28 Sep 2022

·endpts.com

Another Avastin biosimilar joins the party as Roche's grip on the market loosens

Avastin has attracted quite the crowd of biosimilars in recent years, and one more pharma company has elbowed its way in. Regulators on Wednesday approved Celltrion’s biosimilar Vegzelma in six cancer types, including metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube or primary peritoneal cancer. The label is notably missing hepatocellular carcinoma (HCC), which Avastin was approved to treat in combination with Tecentriq back in 2020. Vegzelma is Celltrion’s third cancer biosimilar approved in the US. In the last two months, the drug had already won approval in the EU, UK and Japan. However, the drug is a bit late to the party, as a handful of Avastin biosimilars have gone to market in recent years, including Amgen’s Mvasi, Pfizer’s Zirabev, and Amneal Pharmaceuticals and mAbxience’s Alymsys. Avastin sales have plummeted from $7 billion-plus heights since Amgen’s contender hit the market in 2019. Mvasi was approved in 2017, marking the first biosimilar cleared for the treatment of cancer in the US. Amgen rolled out the drug at a 15% discount from Avastin, charging $677.40 per 100 mg and $2,709.60 per 400 mg. Chasing Roche's aging blockbuster franchise, Amgen/Allergan roll out Avastin, Herceptin knockoffs at discount Last year, Avastin raked in a mere $3.1 billion in the US, down 37% due to sales “strongly impacted” by the uptake of biosimilars, the company reported. Meanwhile, Outlook Therapeutics is looking to bring a bevacizumab biosimilar, the active compound in Avastin, to market for ophthalmic indications. The company withdrew a BLA back in May for wet AMD after the FDA requested additional information, then resubmitted last month. Microcap's effort to take on Eylea with Avastin biosimilar faces significant FDA roadblock Analysts at Cardinal Health called last year one of the “most eventful” in US biosimilars’ history, noting milestones such as Viatris’ Semglee as the first interchangeable biosimilar and the first OK for a biosimilar in ophthalmology, Biogen’s Byooviz. Researchers say biosimilars are on track to reduce US drug expenditure by $133 billion by 2025. Momentum is “stronger than ever,” specialty solutions president Heidi Hunter told Endpoints News back in February, adding that this year could be a “turning point.”

Biosimilar

100 Deals associated with Bevacizumab-BVZR

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC07	DB00112

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Colonic Cancer	EU	Pfizer Europe MA EEIG	14 Feb 2019
Colonic Cancer	LI	Pfizer Europe MA EEIG	14 Feb 2019
Colonic Cancer	IS	Pfizer Europe MA EEIG	14 Feb 2019
Colonic Cancer	NO	Pfizer Europe MA EEIG	14 Feb 2019
Metastatic breast cancer	LI	Pfizer Europe MA EEIG	14 Feb 2019
Metastatic breast cancer	NO	Pfizer Europe MA EEIG	14 Feb 2019
Metastatic breast cancer	EU	Pfizer Europe MA EEIG	14 Feb 2019
Metastatic breast cancer	IS	Pfizer Europe MA EEIG	14 Feb 2019
Non-Small Cell Lung Cancer	IS	Pfizer Europe MA EEIG	14 Feb 2019
Non-Small Cell Lung Cancer	EU	Pfizer Europe MA EEIG	14 Feb 2019
Non-Small Cell Lung Cancer	NO	Pfizer Europe MA EEIG	14 Feb 2019
Non-Small Cell Lung Cancer	LI	Pfizer Europe MA EEIG	14 Feb 2019
Rectal Cancer	NO	Pfizer Europe MA EEIG	14 Feb 2019
Rectal Cancer	EU	Pfizer Europe MA EEIG	14 Feb 2019
Rectal Cancer	IS	Pfizer Europe MA EEIG	14 Feb 2019
Rectal Cancer	LI	Pfizer Europe MA EEIG	14 Feb 2019
Uterine Cervical Cancer	LI	Pfizer Europe MA EEIG	14 Feb 2019
Uterine Cervical Cancer	IS	Pfizer Europe MA EEIG	14 Feb 2019
Uterine Cervical Cancer	NO	Pfizer Europe MA EEIG	14 Feb 2019
Uterine Cervical Cancer	EU	Pfizer Europe MA EEIG	14 Feb 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-squamous non-small cell lung cancer	Discovery	GR	Pfizer Inc.	01 Apr 2015
Non-squamous non-small cell lung cancer	Discovery	PH	Pfizer Inc.	01 Apr 2015
Non-squamous non-small cell lung cancer	Discovery	BR	Pfizer Inc.	01 Apr 2015
Non-squamous non-small cell lung cancer	Discovery	IT	Pfizer Inc.	01 Apr 2015
Non-squamous non-small cell lung cancer	Discovery	CL	Pfizer Inc.	01 Apr 2015
Non-squamous non-small cell lung cancer	Discovery	HR	Pfizer Inc.	01 Apr 2015
Non-squamous non-small cell lung cancer	Discovery	TW	Pfizer Inc.	01 Apr 2015
Non-squamous non-small cell lung cancer	Discovery	CZ	Pfizer Inc.	01 Apr 2015
Non-squamous non-small cell lung cancer	Discovery	IN	Pfizer Inc.	01 Apr 2015
Non-squamous non-small cell lung cancer	Discovery	RU	Pfizer Inc.	01 Apr 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04325698 (CTgov)	Phase 3	Non-squamous non-small cell lung cancer	8	PF-06439535 (PF-06439535 (CN))	qsgyxddnis(vmkjghutnj) = zqvkfqdtcs bvxjkebgkc (xojbouionm, bgxbhrkgig - xnmatrnmwn) View more	-	01 Oct 2024
				Bevacizumab (Bevacizumab (EU))	qsgyxddnis(vmkjghutnj) = llqlamkjqt bvxjkebgkc (xojbouionm, eagvtrnebf - fjyyfuhtpn) View more
NCT02364999 (Pubmed \| Cancer Chemother Pharmacol)	Phase 3	Advanced Lung Non-Squamous Non-Small Cell Carcinoma	719	PF-06439535	(mazzbvamtw) = audhhbjfmr jkijcxersb (gctszpwlsy ) View more	-	01 Mar 2020
NCT02364999 (Pubmed \| BioDrugs)	Phase 3	Advanced Lung Non-Squamous Non-Small Cell Carcinoma First line	719	PF-06439535 plus paclitaxelPF-06439535 plus paclitaxel and carboplatin	(qkkkbzmazz) = egcuamlcoz obpkdwhcbl (tvsapcwamc, 40.01 - 50.57)	-	01 Oct 2019
				bevacizumab-EU plus paclitaxel and carboplatin	(qkkkbzmazz) = oftrwmgkqd obpkdwhcbl (tvsapcwamc, 39.40 - 49.89)
WCLC2019	Not Applicable	EGFR-mutated non-small Cell Lung Cancer	16	Afatinib 30 mg/day	(tyjrftrbzm) = vstzxoqibb kytpxhufhm (huvlgdsjrk ) View more	-	08 Sep 2019
				Bevacizumab 15 mg/kg	(tyjrftrbzm) = wjswlranzh kytpxhufhm (huvlgdsjrk )
NCT02364999 (CTgov)	Phase 3	Non-squamous non-small cell lung cancer	719	Carboplatin+Paclitaxel+Bevacizumab-EU	vobsflfvck(dugcguzher) = twraiaybbw vnylkmqdiu (jveglhbfcu, ohrfyvodsd - mgnduhtsql) View more	-	27 Jun 2018
NCT02364999 (ASCO2018) Manual	Phase 3	Non-squamous non-small cell lung cancer First line	719	paclitaxel+carboplatin+PF-06439535	(lmcvipwdxn) = zgbyzttjwy hexgigjupv (gqcahqzkoz, 40.01 - 50.57) View more	Similar	04 Jun 2018
				paclitaxel+carboplatin+bevacizumab	(lmcvipwdxn) = bgncoegxje hexgigjupv (gqcahqzkoz, 39.40 - 49.89) View more
NCT02031991 (REFLECTIONS B739-01, WCLC2015)	Phase 1	First line	102	PF-06439535	stbljpwjky(pqzmtiktoa) = jwcjvjapoj xqzuxnnewn (mqhhptrhtr, 876)	-	07 Sep 2015
				Bevacizumab-EU	stbljpwjky(pqzmtiktoa) = jhcjxfhbdk xqzuxnnewn (mqhhptrhtr, 2260)
TORG 1014 (WCLC2013)	Not Applicable	Advanced Lung Non-Small Cell Squamous Carcinoma	21	Docetaxel 60 mg/m2 + Bevacizumab 15 mg/kg	(yprtrgngfy) = voeeztvckc axuewbrdol (pkwbqhhqdr ) View more	-	30 Oct 2013
				Docetaxel 50 mg/m2 + Bevacizumab 15 mg/kg	(yprtrgngfy) = hvkrxgpfny axuewbrdol (pkwbqhhqdr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis